A phase 2 clinical trial has demonstrated that bimagrumab, when combined with semaglutide, resulted in significant weight loss for trial participants while maintaining lean muscle mass suggesting a promising approach for Weight loss with GLP 1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine Precision obesity medicine: A phenotype guided framework for pharmacologic therapy across the lifespan Journal of Endocrinological Investigation Springer Nature Link PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar